<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144170</url>
  </required_header>
  <id_info>
    <org_study_id>1182.48</org_study_id>
    <secondary_id>RESIST 2</secondary_id>
    <nct_id>NCT00144170</nct_id>
  </id_info>
  <brief_title>Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)</brief_title>
  <official_title>Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir
      versus an active control arm in highly treatment experienced Human immunodeficiency virus-1
      infected patients. Patients must have a viral load &gt; =1000 cells/mL, and genotype indicating
      at least one resistance conferring protease inhibitor-mutation as determined from a
      predefined panel of mutations. Any CD4+ count is acceptable.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response at Week 48</measure>
    <time_frame>after 48 weeks of treatment</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Treatment Failure Through 48 Weeks of Treatment</measure>
    <time_frame>after 48 weeks of treatment</time_frame>
    <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with Log(baseline Viral Load) - Log(on-treatment Viral Load) &lt; 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 2</measure>
    <time_frame>week 2</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 16</measure>
    <time_frame>week 16</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 32</measure>
    <time_frame>week 32</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 40</measure>
    <time_frame>week 40</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 56</measure>
    <time_frame>week 56</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 64</measure>
    <time_frame>week 64</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 72</measure>
    <time_frame>week 72</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 80</measure>
    <time_frame>week 80</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 88</measure>
    <time_frame>week 88</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 96</measure>
    <time_frame>after 96 weeks of treatment</time_frame>
    <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure Through 96 Weeks of Treatment</measure>
    <time_frame>after 96 weeks of treatment</time_frame>
    <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with Log(baseline Viral Load) - Log(on-treatment Viral Load) &lt; 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Confirmed Virologic Failure Through 48 Weeks of Treatment</measure>
    <time_frame>after 48 weeks of treatment</time_frame>
    <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement where the Log(baseline viral load)-Log(on-treatment viral load)&gt;1 before a 2 consecutive measurements where Log(baseline viral load)-Log(on-treatment viral load)&lt;1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Confirmed Virologic Failure Through 96 Weeks of Treatment</measure>
    <time_frame>after 96 weeks of treatment</time_frame>
    <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement where the Log(baseline viral load)-Log(on-treatment viral load)&gt;1 before a 2 consecutive measurements where Log(baseline viral load)-Log(on-treatment viral load)&lt;1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response</measure>
    <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 16</measure>
    <time_frame>week 16</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 24</measure>
    <time_frame>week 24</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 32</measure>
    <time_frame>week 32</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 40</measure>
    <time_frame>week 40</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 48</measure>
    <time_frame>week 48</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 56</measure>
    <time_frame>week 56</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 64</measure>
    <time_frame>week 64</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 80</measure>
    <time_frame>Week 80</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 88</measure>
    <time_frame>Week 88</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 2)</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 4)</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 8)</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 16)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 24)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 32)</measure>
    <time_frame>Baseline to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 40)</measure>
    <time_frame>Baseline to Week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 48)</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 56)</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 64)</measure>
    <time_frame>Baseline to Week 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 72)</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 80)</measure>
    <time_frame>Baseline to Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 88)</measure>
    <time_frame>Baseline to Week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load (Week 96)</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 40</measure>
    <time_frame>Week 40</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Viral Load Nadir During Study Treatment Through 96 Weeks</measure>
    <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 32</measure>
    <time_frame>Week 32</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 56</measure>
    <time_frame>Week 56</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 64</measure>
    <time_frame>Week 64</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 80</measure>
    <time_frame>Week 80</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 88</measure>
    <time_frame>week 88</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 96</measure>
    <time_frame>week 96</time_frame>
    <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response</measure>
    <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 32</measure>
    <time_frame>Week 32</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 40</measure>
    <time_frame>Week 40</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 56</measure>
    <time_frame>Week 56</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 64</measure>
    <time_frame>Week 64</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 80</measure>
    <time_frame>Week 80</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 88</measure>
    <time_frame>Week 88</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 2)</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 4)</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 8)</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 16)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 24)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 32)</measure>
    <time_frame>Baseline to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 40)</measure>
    <time_frame>Baseline to Week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 48)</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 56)</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 64)</measure>
    <time_frame>Baseline to Week 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 72)</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 80)</measure>
    <time_frame>Baseline to Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 88)</measure>
    <time_frame>Baseline to Week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count (Week 96)</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to New Centers for Disease Control (CDC) Class C Progression Event or Death.</measure>
    <time_frame>up to 75 weeks of treatment</time_frame>
    <description>Time to death or occurrence of AIDS-defining condition according to the US Centers for Disease Control and Prevention case definition.
The median and quartiles are underestimated since more than 92% of the observations (in both treatment arms) were censored and the estimation was restricted to the largest observed event time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">882</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Tipranavir(TPV)/low dose ritonavir(r)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator protease inhibitor(CPI)/low dose ritonavir(r)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir (with low dose ritonavir)</intervention_name>
    <arm_group_label>Tipranavir(TPV)/low dose ritonavir(r)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator protease inhibitor(CPI)/low dose ritonavir(r)</intervention_name>
    <arm_group_label>Comparator protease inhibitor(CPI)/low dose ritonavir(r)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent prior to trial participation.

          2. Human immunodeficiency virus-1 infected males or females &gt;=18 years of age.

          3. Screening genotypic resistance report indicating both of the following:

               -  at least one primary protease mutation at the following sites 30N, 46I/L, 48V,
                  50V, 82A/F/L/T, 84V or 90M , and

               -  no more than two protease mutations on codons 33, 82, 84, or 90.

          4. At least 3 consecutive months experience taking antiretrovirals from each of the
             classes of Nucleoside reverse transcriptase inhibitor(s), Non-nucleoside reverse
             transcriptase inhibitor(s), and Protease inhibitor(s) at some point in treatment
             history,

               -  with at least 2 Protease inhibitor-based regimens (minimum 3 months of exposure
                  of each), one of which must be part of the current regimen, and

               -  current Protease inhibitor-based antiretroviral medication regimen for at least 3
                  months prior to randomisation.

          5. Human immunodeficiency virus-1 viral load &gt;=1000 copies/mL at screening.

          6. Acceptable screening laboratory values that indicate adequate baseline organ function.
             Laboratory values are considered to be acceptable if the following apply:

               -  Total cholesterol &lt;=400 mg/dl or 10,36 mm/L.

               -  Total triglycerides &lt;=750 mg/dl or 8,5 mm/L.

               -  Alanine aminotransferase &lt;=3x upper limit of normal and aspartate
                  aminotransferase &lt;=2.5x upper limit of normal.

               -  Any Grade gamma-glutamyl transpeptidase is acceptable.

               -  Any Grade creatinine kinase is acceptable as long as there is no concurrent
                  myopathy.

               -  All other laboratory test values &lt;= Grade 1(Division of Acquired immune
                  deficiency syndrome, National Institute of Health grading scale).

          7. Acceptable medical history, as assessed by the investigator, with chest X-ray and
             electrocardiogram within 1 year of study participation.

          8. Willingness to abstain from ingesting substances during the study which may alter
             plasma study drug levels by interaction with the cytochrome P450 system.

          9. A prior Acquired immune deficiency syndrome-defining event is acceptable as long as it
             has resolved or the patient has been on stable treatment for at least 2 months
             (Acquired immune deficiency syndrome related complex is acceptable).

        Exclusion Criteria:

          1. Antiretroviral medication naïve.

          2. Patients on recent drug holiday, defined as off antiretroviral medications for at
             least 7 consecutive days within the last 3 months.

          3. Alanine aminotransferase &gt;3x upper limit of normal and aspartate aminotransferase
             &gt;2.5x upper limit of normal at either screening visit.

          4. Female patients of child-bearing potential who:

               -  have a positive serum pregnancy test at screening or during the study,

               -  are breast feeding

               -  are planning to become pregnant, or

               -  are not willing to use a barrier method of contraception, or

               -  require ethinyl estradiol administration

          5. Prior tipranavir use.

          6. Use of investigational medications within 30 days before study entry or during the
             trial. (T-20 [enfuvirtide] and Tenofovir (Viread), investigational at the time of
             writing of this protocol, will be allowed.)

          7. Use of immunomodulatory drugs within 30 days before study entry or during the trial
             (e.g. interferon, cyclosporin, hydroxyurea, interleukin 2).

          8. Inability to adhere to the requirements of the protocol, including active substance
             abuse as assessed by the investigator.

          9. In the opinion of the investigator, likely survival of less than 12 months because of
             underlying disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1182.48.5401 Fundación Huésped</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5402 Fundación Huésped</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5403 Servicio de Infecciosas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5404 Servicio de Infecciosas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5405 Hospital Muniz</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5406 Servicio de Immunocomprometido</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Luxembourg</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5512 Cidade Universitária Zeferino Vaz-Clínica Médica FCM</name>
      <address>
        <city>Campinas - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5505 Instituto A-Z de Pesquisa e Ensino da PUC</name>
      <address>
        <city>Curitiba - PR</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5507 Hospital Geral de Nova Iguaçu - Ministério da Saúde</name>
      <address>
        <city>Nova Iguaçu - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5502 Fundação Oswaldo Cruz</name>
      <address>
        <city>Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5509 Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5511 Universidade Federal da Bahia-Unidade Docente Assistencial d</name>
      <address>
        <city>Salvador - BA</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5501 Clínica de Doenças Parasitárias e Infecciosas-Hospital Dia</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5503 I.I. Emilio Ribas - Moléstias Infecciosas</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5504 Hospital do Servidor Público Estadual - IAMSPE</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5506 Centro de Referência e Treinamento - DST/AIDS</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5508 I.I. Emilio Ribas</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5510 INCOR e Hospital das Clínicas da Universidade de São Paulo</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5513 UNIFESP - Centro de Pesquisa Clinica</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus N</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København Ø</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3311 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Besancon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3317 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 02</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3322 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3309 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3318 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3316 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3323 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 14</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 18</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3319 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3310 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3312 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3321 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3315 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3313 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3314 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3320 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4918 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4912 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4914 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4924 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4930 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg/Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4928 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4916 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4929 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4931 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4913 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4920 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4926 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4923 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4915 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4919 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4921 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4927 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goudi, Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Peraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3531 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3930 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3920 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antella (fi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3926 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3932 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3929 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busto Arsizio (va)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3917 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3919 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3927 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3925 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Macerata</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3924 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3934 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3915 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3912 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3921 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3916 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3922 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3935 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3914 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3931 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3933 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5201 Centro Médico La Raza IMSS</name>
      <address>
        <city>Mexico, D.F.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5202 Hospital Lopez Mateos</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5203 Centro Guadalajara, Jal.</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.5206 Centro Medico San Vicente</name>
      <address>
        <city>Monterrey, N.l.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cascais</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3505 Hospital Egas Moniz</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3504 Hospital de São João</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3415 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3417 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3416 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3413 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3414 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3420 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.3418 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4101 Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4104 Hopital Universitaire de Genève</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4103 Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4102 Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4414 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4418 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4417 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.48.4407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <results_first_submitted>September 11, 2009</results_first_submitted>
  <results_first_submitted_qc>November 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2009</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The discrepancy with enrollment number in the protocol section is due to 16 patients not treated. (7 from TPV/r and 9 from CPI/r). These patients were not included in any analyses or results.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
        </group>
        <group group_id="P2">
          <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="438"/>
                <participants group_id="P2" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="396"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="316"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
        </group>
        <group group_id="B2">
          <title>Comparitor Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="435"/>
            <count group_id="B2" value="428"/>
            <count group_id="B3" value="863"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>3 patients were not randomized but treated with TPV/r. They are included in the participant flow and adverse events but not in the efficacy analysis.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.5" spread="8.4"/>
                    <measurement group_id="B2" value="42.9" spread="8"/>
                    <measurement group_id="B3" value="42.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>3 patients were not randomized but treated with TPV/r. They are included in the participant flow and adverse events but not in the efficacy analysis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Response at Week 48</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>after 48 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 48</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.9</ci_lower_limit>
            <ci_upper_limit>24.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Treatment Failure Through 48 Weeks of Treatment</title>
        <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with Log(baseline Viral Load) - Log(on-treatment Viral Load) &lt; 1.</description>
        <time_frame>after 48 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure Through 48 Weeks of Treatment</title>
          <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with Log(baseline Viral Load) - Log(on-treatment Viral Load) &lt; 1.</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="0" upper_limit="475"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 2</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 2</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 2</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>24.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.6</ci_lower_limit>
            <ci_upper_limit>31.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 4</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 4</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 4</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1"/>
                    <measurement group_id="O2" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>28.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.5</ci_lower_limit>
            <ci_upper_limit>35.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 8</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 8</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 8</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3"/>
                    <measurement group_id="O2" value="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>29.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.2</ci_lower_limit>
            <ci_upper_limit>35.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 16</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 16</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 16</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>26.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.5</ci_lower_limit>
            <ci_upper_limit>32.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 24</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 24</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 24</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>22.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.2</ci_lower_limit>
            <ci_upper_limit>27.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 32</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 32</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 32</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>19.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.3</ci_lower_limit>
            <ci_upper_limit>24.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 40</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 40</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 40</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.0</ci_lower_limit>
            <ci_upper_limit>24.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 56</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 56</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 56</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.7</ci_lower_limit>
            <ci_upper_limit>22.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 64</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 64</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 64</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.7</ci_lower_limit>
            <ci_upper_limit>22.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 72</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 72</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 72</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.0</ci_lower_limit>
            <ci_upper_limit>22.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 80</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 80</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 80</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.2</ci_lower_limit>
            <ci_upper_limit>21.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 88</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 88</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 88</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.1</ci_lower_limit>
            <ci_upper_limit>21.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 96</title>
        <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>after 96 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 96</title>
          <description>Patients who experienced treatment response. Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.6</ci_lower_limit>
            <ci_upper_limit>20.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure Through 96 Weeks of Treatment</title>
        <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with Log(baseline Viral Load) - Log(on-treatment Viral Load) &lt; 1.</description>
        <time_frame>after 96 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure Through 96 Weeks of Treatment</title>
          <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with Log(baseline Viral Load) - Log(on-treatment Viral Load) &lt; 1.</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="0" upper_limit="811"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Confirmed Virologic Failure Through 48 Weeks of Treatment</title>
        <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement where the Log(baseline viral load)-Log(on-treatment viral load)&gt;1 before a 2 consecutive measurements where Log(baseline viral load)-Log(on-treatment viral load)&lt;1.</description>
        <time_frame>after 48 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Confirmed Virologic Failure Through 48 Weeks of Treatment</title>
          <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement where the Log(baseline viral load)-Log(on-treatment viral load)&gt;1 before a 2 consecutive measurements where Log(baseline viral load)-Log(on-treatment viral load)&lt;1.</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="0" upper_limit="475"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Confirmed Virologic Failure Through 96 Weeks of Treatment</title>
        <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement where the Log(baseline viral load)-Log(on-treatment viral load)&gt;1 before a 2 consecutive measurements where Log(baseline viral load)-Log(on-treatment viral load)&lt;1.</description>
        <time_frame>after 96 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Confirmed Virologic Failure Through 96 Weeks of Treatment</title>
          <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement where the Log(baseline viral load)-Log(on-treatment viral load)&gt;1 before a 2 consecutive measurements where Log(baseline viral load)-Log(on-treatment viral load)&lt;1.</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="0" upper_limit="756"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6"/>
                    <measurement group_id="O2" value="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 2</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>Week 2</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 2</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 4</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 4</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 4</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                    <measurement group_id="O2" value="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 8</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 8</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 8</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                    <measurement group_id="O2" value="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 16</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 16</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 16</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 24</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 24</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 24</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8"/>
                    <measurement group_id="O2" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 32</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 32</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 32</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 40</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 40</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 40</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 48</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 48</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 48</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 56</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 56</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 56</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 64</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>week 64</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 64</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 72</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>Week 72</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 72</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 80</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>Week 80</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 80</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 88</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>Week 88</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 88</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 96</title>
        <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
        <time_frame>Week 96</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 96</title>
          <description>Virologic response is defined as: Log(baseline viral load (VL))-Log(on-treatment VL)&gt;=1</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 2)</title>
        <time_frame>Baseline to Week 2</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 2)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" lower_limit="-1.78" upper_limit="-0.55"/>
                    <measurement group_id="O2" value="-0.56" lower_limit="-1.28" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 4)</title>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 4)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" lower_limit="-2.03" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-0.42" lower_limit="-1.35" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 8)</title>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 8)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-2.25" upper_limit="-0.22"/>
                    <measurement group_id="O2" value="-0.33" lower_limit="-1.23" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 16)</title>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 16)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" lower_limit="-2.35" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-0.93" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 24)</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 24)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" lower_limit="-2.28" upper_limit="-0.11"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-0.86" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 32)</title>
        <time_frame>Baseline to Week 32</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 32)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" lower_limit="-2.29" upper_limit="-0.09"/>
                    <measurement group_id="O2" value="-0.24" lower_limit="-0.84" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 40)</title>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 40)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-2.27" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.73" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 48)</title>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 48)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-2.17" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.75" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 56)</title>
        <time_frame>Baseline to Week 56</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 56)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" lower_limit="-2.16" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="-0.22" lower_limit="-0.74" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 64)</title>
        <time_frame>Baseline to Week 64</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 64)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" lower_limit="-2.12" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-0.71" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 72)</title>
        <time_frame>Baseline to Week 72</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 72)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" lower_limit="-2.14" upper_limit="-0.05"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.7" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 80)</title>
        <time_frame>Baseline to Week 80</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 80)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" lower_limit="-2.14" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.72" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 88)</title>
        <time_frame>Baseline to Week 88</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 88)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" lower_limit="-2.12" upper_limit="-0.03"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.7" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load (Week 96)</title>
        <time_frame>Baseline to Week 96</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load (Week 96)</title>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" lower_limit="-2.14" upper_limit="-0.05"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.67" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 40</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 40</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 40</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Viral Load Nadir During Study Treatment Through 96 Weeks</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Viral Load Nadir During Study Treatment Through 96 Weeks</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 2</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 2</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 2</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 4</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 4</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 4</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 8</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 8</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 8</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 16</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 16</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 16</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 24</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 24</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 24</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 32</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 32</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 32</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4"/>
                    <measurement group_id="O2" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 48</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 48</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 56</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 56</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 56</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 64</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 64</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 64</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 72</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 72</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 72</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 80</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>Week 80</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 80</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 88</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>week 88</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 88</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 96</title>
        <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
        <time_frame>week 96</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 96</title>
          <description>Virologic response defined as Viral Load&lt;400 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 2</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 2</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 2</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 4</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 4</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 4</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 8</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 8</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 8</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 16</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 16</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 16</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 24</title>
        <description>Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 24</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 24</title>
          <description>Viral Load &lt; 50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 32</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 32</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 32</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 40</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 40</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 40</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 48</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 48</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 56</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 56</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 56</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 64</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 64</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 64</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 72</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 72</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 72</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 80</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 80</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 80</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 88</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 88</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 88</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response at Week 96</title>
        <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
        <time_frame>Week 96</time_frame>
        <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response at Week 96</title>
          <description>Virologic response defined as Viral Load&lt;50 copies/mL</description>
          <population>Full Analysis Set (FAS), included all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 2)</title>
        <time_frame>Baseline to Week 2</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 2)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="65"/>
                    <measurement group_id="O2" value="13" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 4)</title>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 4)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="77"/>
                    <measurement group_id="O2" value="19" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 8)</title>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 8)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="85"/>
                    <measurement group_id="O2" value="25" spread="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 16)</title>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 16)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="90"/>
                    <measurement group_id="O2" value="25" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 24)</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 24)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="97"/>
                    <measurement group_id="O2" value="21" spread="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 32)</title>
        <time_frame>Baseline to Week 32</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 32)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="102"/>
                    <measurement group_id="O2" value="17" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 40)</title>
        <time_frame>Baseline to Week 40</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 40)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="99"/>
                    <measurement group_id="O2" value="19" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 48)</title>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 48)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="109"/>
                    <measurement group_id="O2" value="16" spread="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 56)</title>
        <time_frame>Baseline to Week 56</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 56)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="113"/>
                    <measurement group_id="O2" value="16" spread="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 64)</title>
        <time_frame>Baseline to Week 64</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 64)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="125"/>
                    <measurement group_id="O2" value="13" spread="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 72)</title>
        <time_frame>Baseline to Week 72</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 72)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="129"/>
                    <measurement group_id="O2" value="18" spread="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 80)</title>
        <time_frame>Baseline to Week 80</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 80)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="125"/>
                    <measurement group_id="O2" value="19" spread="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 88)</title>
        <time_frame>Baseline to Week 88</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 88)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="138"/>
                    <measurement group_id="O2" value="19" spread="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count (Week 96)</title>
        <time_frame>Baseline to Week 96</time_frame>
        <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count (Week 96)</title>
          <population>Full Analysis Set having baseline CD4 (FAS CD4), included all randomized patients treated with at least one dose of study medication having baseline CD4 count</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="132"/>
                    <measurement group_id="O2" value="20" spread="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to New Centers for Disease Control (CDC) Class C Progression Event or Death.</title>
        <description>Time to death or occurrence of AIDS-defining condition according to the US Centers for Disease Control and Prevention case definition.
The median and quartiles are underestimated since more than 92% of the observations (in both treatment arms) were censored and the estimation was restricted to the largest observed event time.</description>
        <time_frame>up to 75 weeks of treatment</time_frame>
        <population>Safety Set (SAF), included all patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          </group>
          <group group_id="O2">
            <title>Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
          </group>
        </group_list>
        <measure>
          <title>Time to New Centers for Disease Control (CDC) Class C Progression Event or Death.</title>
          <description>Time to death or occurrence of AIDS-defining condition according to the US Centers for Disease Control and Prevention case definition.
The median and quartiles are underestimated since more than 92% of the observations (in both treatment arms) were censored and the estimation was restricted to the largest observed event time.</description>
          <population>Safety Set (SAF), included all patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528" lower_limit="528" upper_limit="528"/>
                    <measurement group_id="O2" value="332" lower_limit="332" upper_limit="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1026</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>240 weeks</time_frame>
      <desc>3 patients were not randomized but treated with TPV/r. They are included in the participant flow and adverse events but not in the efficacy analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
        </group>
        <group group_id="E2">
          <title>Comparitor Protease Inhibitor(CPI)/Low Dose Ritonavir(r)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Haematotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Retinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Actinomycotic pulmonary infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cryptosporidiosis infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cyclosporidium infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Disseminated cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gastroenteritis cryptosporidial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Haemophilus sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Helicobacter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Herpes oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Isosporiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Nocardiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Visceral leishmaniasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident at home</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hyperamylasaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Mitochondrial toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anal cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease mixed cellularity stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Recurrent cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Uterine carcinoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cerebral ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cervical root pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Nephrogenic diabetes insipidus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pulmonary cavitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Vocal cord thickening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Eventration procedure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="359" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

